XGN_OUT_1 [2025-04-29 09:11:08 -0400] 4783 Bytes | 1437 tokens | Cum: 1437 tkns (17.96% of 8k)
==========================================================================

A volatile market is a logical market. It is 9:11 AM on Tue Apr 29, 2025. Exagen (XGN) surges from $6.21 to $6.78. Analyze we shall, without fear or favor.

--- COMPANY PROFILE ---
Company: Exagen (XGN)
IPO: IPO date unknown
Shares Outstanding: 17,900,000
Industry: SERVICES-MEDICAL LABORATORIES
Exchange: XNAS

Here’s a list of headlines for Exagen:

Apr-28-25 09:00AM - Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors
Apr-26-25 03:31AM - Exagen: Buy An Undervalued Diagnostics Developer That Is On The Path To Profitability
Apr-21-25 04:05PM - Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025
Mar-12-25 03:04AM - Exagen Inc (XGN) Q4 2024 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives
Mar-12-25 03:04AM 12:10AM - Q4 2024 Exagen Inc Earnings Call
Mar-11-25 09:15AM - Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
Mar-11-25 09:15AM 08:00AM - Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights
Feb-25-25 04:05PM - Exagen Inc. to Announce Fourth Quarter and Full-Year 2024 Financial Results on March 11, 2025
Feb-05-25 06:38AM - Strength Seen in Exagen (XGN): Can Its 29.4% Jump Turn into More Strength?
Feb-04-25 04:05PM - Exagen Inc. to Participate in Upcoming Investor Conferences
Jan-12-25 12:00PM - Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
Dec-12-24 09:00AM - Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE CTD
Nov-14-24 04:30PM - Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE CTD Platform
Nov-13-24 04:05PM - Exagen Inc. to Participate in Fourth Quarter Investor Conferences
Nov-13-24 04:05PM 02:09AM - Exagen Inc (XGN) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic Growth ...
Nov-13-24 04:05PM 12:51AM - Q3 2024 Exagen Inc Earnings Call
Nov-12-24 09:25AM - Exagen Inc. (XGN) Reports Q3 Loss, Misses Revenue Estimates
Nov-11-24 07:25AM - Exagen Inc (XGN) Q3 2024 Earnings Report Preview: What To Expect
Oct-29-24 04:05PM - Exagen to Announce Third Quarter 2024 Results on November 12, 2024
Oct-21-24 04:05PM - Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence
Sep-04-24 04:05PM - Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
Aug-29-24 09:55AM - Bears are Losing Control Over Exagen (XGN), Here's Why It's a 'Buy' Now

Prior AI Reports for XGN:
1. 2025-04-02 – Score: 55 – Target: 6.5000 – Highs: 4.6400 / 4.4100 / 4.15
mixed-performance-and-insider-sell-offs-raise-concerns-earnings-awaited

(Note: Highs = Same day / 2nd day / 3rd day)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2024-06-13T12:50:02Z - Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors
B2 - 2024-06-10T12:03:00Z - Time to Play 5 Top-Ranked Stocks With Rising P/E?
B3 - 2024-05-13T13:10:02Z - Exagen Inc. (XGN) Reports Q1 Loss, Tops Revenue Estimates
B4 - 2024-05-07T21:10:03Z - Quanterix Corporation (QTRX) Reports Q1 Loss, Tops Revenue Estimates
B5 - 2024-04-30T20:05:00Z - Exagen to Announce First Quarter 2024 Results on May 13, 2024
B6 - 2024-04-26T12:30:00Z - Exagen Inc. Announces Changes to the Board of Directors

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Exagen (XGN).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

XGN_OUT_3 [2025-04-29 09:11:08 -0400] 769 Bytes | 204 tokens | Cum: 1643 tkns (20.54% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Why Fast-paced Mover Exagen (XGN) Is a Great Choice for Value Investors**Date: Unknown DateSource: Unknown SourceURL: https://www.zacks.com/stock/news/2287718/why-fast-paced-mover-exagen-xgn-is-a-great-choice-for-value-investorsIf you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Exagen (XGN) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XGN_OUT_5 [2025-04-29 09:11:09 -0400] 964 Bytes | 272 tokens | Cum: 1917 tkns (23.96% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-28T13:22:50Z - Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors...
A2 - 2025-04-28T13:06:14Z - Exagen secures $75 million credit facility with Perceptive Advisors By Investing.com...
A3 - 2025-04-28T13:15:13Z - Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors | Taiwan News | Apr. 2...
A4 - 2025-04-28T13:07:30Z - Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors...
A5 - 2025-04-26T07:35:24Z - Exagen: Buy An Undervalued Diagnostics Developer That Is On Path To Profitability (XGN)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

XGN_OUT_7 [2025-04-29 09:11:10 -0400] 1182 Bytes | 322 tokens | Cum: 2241 tkns (28.01% of 8k)
==========================================================================

Showing A1 (chunk 1 of 10): A1:
**Exagen Inc. Announces Senior Secured Credit Facility with Perceptive Advisors**Date: 2025-04-28Source: {'uri': 'manilatimes.net', 'dataType': 'news', 'title': 'The Manila times'}URL: https://www.manilatimes.net/2025/04/28/tmt-newswire/globenewswire/exagen-inc-announces-senior-secured-credit-facility-with-perceptive-advisors/2100680Check Point Software Achieves FedRAMP "In Process" Milestone to Deliver AI-Powered Cyber Security Solutions to U.S. Government

$25 Million Funded at Close to Refinance Existing Debt and Extend Maturity

Additional Borrowing Capacity Provides Minimally Dilutive Growth Capital

CARLSBAD, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced it has entered into an agreement with Perceptive Advisors LLC for a term loan credit facility of up to $75 million, with $25 million fu

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XGN_OUT_9 [2025-04-29 09:11:10 -0400] 1182 Bytes | 239 tokens | Cum: 2482 tkns (31.03% of 8k)
==========================================================================

Showing A1 (chunk 2 of 10): nded at closing to retire an existing debt facility and strengthen the balance sheet.

"I'm pleased to announce our new debt facility with Perceptive Advisors, a highly respected life sciences investor with a deep understanding of our industry. This strategic partnership extends our amortization timeline, strengthens our balance sheet and provides optionality to accelerate future growth initiatives with access to minimally dilutive capital," said John Aballi, President and Chief Executive Officer.

"We are excited to partner with Exagen and its management team on their journey to accelerate personalized medicine in autoimmune disease," said Sam Chawla, Portfolio Manager at Perceptive Advisors. "The Company has a proven track record of advancing diagnoses and providing clinical benefits, and we believe this transaction further enables Exagen to build its leadership position and empower rh

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XGN_OUT_11 [2025-04-29 09:11:11 -0400] 1182 Bytes | 270 tokens | Cum: 2754 tkns (34.42% of 8k)
==========================================================================

Showing A1 (chunk 3 of 10): eumatologists and other healthcare practitioners to greatly enhance patient care."

Get the latest news

delivered to your inbox Sign up for The Manila Times newsletters By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service and Privacy Policy.

On April 25, 2025, Exagen entered into a credit and guaranty agreement pursuant to which Perceptive has agreed to make certain term loans in the aggregate principal amount of up to $75 million. The first $25 million tranche was funded at close and used to retire Exagen's existing term debt facility with Innovatus Capital Partners.

Additional tranches are available at Exagen's election, as follows:

Advertisement

Second Tranche - $10 million available through March 31, 2026, upon and subject to achievement of certain revenue milestones.Third Tranche - $10 million available through December 31, 2026,

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XGN_OUT_13 [2025-04-29 09:11:12 -0400] 1182 Bytes | 286 tokens | Cum: 3042 tkns (38.02% of 8k)
==========================================================================

Showing A1 (chunk 4 of 10): upon and subject to achievement of certain revenue milestones.Business Development Tranche - $30 million available through March 31, 2027, to be funded at the discretion of Perceptive for the Company's business development initiatives.

Interest under the credit agreement is Term SOFR + 7%, with a SOFR floor of 4.75%. Exagen will make interest-only payments for 60 months, with the entire outstanding interest and principal amount due and payable upon maturity. The loan is secured by substantially all of Exagen's assets.

In connection with the initial close, Exagen issued to Perceptive a warrant to purchase 400,000 shares of Exagen common stock, of which 200,000 shares are exercisable at an exercise price of $4.96 per share, equal to the 10-day VWAP immediately prior to the close, and 200,000 are exercisable at an exercise price of $5.58 per share, equal to the 10-day VWAP immediately pr

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XGN_OUT_15 [2025-04-29 09:11:13 -0400] 1182 Bytes | 286 tokens | Cum: 3330 tkns (41.62% of 8k)
==========================================================================

Showing A1 (chunk 5 of 10): ior to the close, plus twelve and one-half percent (12.5%).

An additional up to 750,000 warrants may be issued to Perceptive as follows:

Advertisement

150,000 shares with the closing of each of the Second and Third tranches, and450,000 shares with the closing of the Business Development Tranche The per-share exercise price for 50% of each tranche's shares will be equal to the 10-day VWAP ending on the business day immediately preceding each tranche's funding date. The per-share exercise price for the balance of each tranche's warrants will be equal to the 10-day VWAP immediately preceding the funding date, plus twelve and one-half percent (12.5%) of the 10-day VWAP immediately preceding each tranche's funding date.

Credo 180, Inc. acted as sole financial advisor to Exagen on this transaction.

Additional details regarding the financing will be included on a Form 8-K, which Exagen wil

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XGN_OUT_17 [2025-04-29 09:11:13 -0400] 1185 Bytes | 253 tokens | Cum: 3585 tkns (44.81% of 8k)
==========================================================================

Showing A1 (chunk 6 of 10): l file with the Securities and Exchange Commission within four business days of the closing of the credit agreement.

About Exagen

Advertisement

Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen's mission is to provide clarity in autoimmune disease decision making and improve clinical outcomes through its innovative testing portfolio. The Company's flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren's syndrome earlier and with greater accuracy. Exagen's laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a full suite of AVISE®-branded tests for disease diagn

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XGN_OUT_19 [2025-04-29 09:11:14 -0400] 1182 Bytes | 244 tokens | Cum: 3831 tkns (47.89% of 8k)
==========================================================================

Showing A1 (chunk 7 of 10): osis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.

For more information, please visit Exagen.com or follow @ExagenInc on X (formally known as Twitter).

Forward Looking Statements

Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the potential advantages to the Company of entering into the credit agreement; the potential funding of future tranches pursuant to the credit agreement that are subject to conditions and milestones that may not occur; evaluations and judgements regarding past

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XGN_OUT_21 [2025-04-29 09:11:15 -0400] 1182 Bytes | 239 tokens | Cum: 4072 tkns (50.90% of 8k)
==========================================================================

Showing A1 (chunk 8 of 10): and future performance; and the potential utility and effectiveness of Exagen's services and testing solutions. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen's business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; and changes in laws and regulations related to Exagen's regulatory requirements. Exagen's commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical c

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XGN_OUT_23 [2025-04-29 09:11:16 -0400] 1182 Bytes | 264 tokens | Cum: 4338 tkns (54.23% of 8k)
==========================================================================

Showing A1 (chunk 9 of 10): ommunity; Exagen's ability to successfully execute on its business strategies; third-party payors not providing coverage and adequate reimbursement for Exagen's testing products, including Exagen's ability to collect on funds due; Exagen's ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen's business; and other risks described in Exagen's prior press releases and Exagen's filings with the Securities and Exchange Commission ("SEC"), including under the heading "Risk Factors" in Exagen's Annual Report on Form 10-K for the year ended December 31, 2024, filed with the SEC on March 11, 2025 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements t

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XGN_OUT_25 [2025-04-29 09:11:17 -0400] 675 Bytes | 159 tokens | Cum: 4499 tkns (56.24% of 8k)
==========================================================================

Showing A1 (chunk 10 of 10): o reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Advertisement

Contact:

Ryan Douglas

Exagen Inc.

[email protected]

Advertisement

760.560.1525

Advertisement

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XGN_OUT_27 [2025-04-29 09:11:19 -0400] 1105 Bytes | 308 tokens | Cum: 4809 tkns (60.11% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-04-28 8-K Item1.01 Entry into a Material Definitive Agrmt.

Entry into Perceptive Term Loan Facility

On April 25, 2025 (the Closing Date), Exagen Inc. (the Company) entered into a Credit Agrmt and Guaranty (the Credit Agrmt) with Perceptive Credit Holdings IV, LP, as lender ...

S3 - 2025-03-11 8-K Item 2.02. Results of Oper and Fin Cond.

On March 11, 2025 , the Company reported its financial results for the quarter and year ended December 31, 2024. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report.

The inform...

S4 - 2025-03-11 8-K Item 2.02. Results of Oper and Fin Cond.

On March 11, 2025 , the Company reported its financial results for the quarter and year ended December 31, 2024. A copy of the press release issued by the Company is furnished as Exhibit 99.1 to this report.

The inform...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

XGN_OUT_29 [2025-04-29 09:11:20 -0400] 1181 Bytes | 303 tokens | Cum: 5114 tkns (63.92% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item1.01 Entry into a Material Definitive Agreement.

Entry into Perceptive Term Loan Facility

On April 25, 2025 (the Closing Date), Exagen Inc. (the Company) entered into a Credit Agreement and Guaranty (the Credit Agreement) with Perceptive Credit Holdings IV, LP, as lender and administrative agent (Perceptive), which provides for a senior secured delayed draw term loan facility in an aggregate principal amount of up to $75.0 million (the Perceptive Term Loan Facility). An initial tranche of $25.0 million (the Tranche A Loan) was funded under the Perceptive Term Loan Facility on the Closing Date. In addition to the Tranche A Loan, the Perceptive Term Loan Facility includes (i) available through March 31, 2026, an additional Tranche B Loan in an aggregate amount of up to $10.0 million (the Tranche B Loan), (ii) available from March 31, 2026 through December 31, 2026, an additiona

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XGN_OUT_31 [2025-04-29 09:11:21 -0400] 1181 Bytes | 299 tokens | Cum: 5415 tkns (67.69% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): l Tranche C Loan in an aggregate amount of up to $10.0 million (the Tranche C Loan) and (iii) until December 31, 2027, an additional Tranche D Loan in an aggregate amount of up to $30.0 million (the Tranche D Loan and together with the Tranche A Loan, the Tranche B Loan, and the Tranche C Loan, the Term Loans), each of which will be accessible by the Company so long as the Company satisfies certain customary conditions precedent, including specified revenue milestones (the funding date of the Tranche B Loan, the Tranche B Borrowing Date, the funding date of the Tranche C Loan, the Tranche C Borrowing Date, and the funding date of the Tranche D Loan, the Tranche D Borrowing Date) and, for the Tranche D Loan, subject to certain business development milestones. The Perceptive Term Loan Facility has a maturity date of April 25, 2030 (the Maturity Date) and provides for an interest-only perio

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XGN_OUT_33 [2025-04-29 09:11:24 -0400] 1181 Bytes | 286 tokens | Cum: 5703 tkns (71.29% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): d during the term of the loan with principal due at the Maturity Date. The Companys net proceeds from the Tranche A Loan were approximately $22.8 million, after deducting estimated debt issuance costs, fees and expenses and excluding any repayment of existing debt.

Interest Rate

The Perceptive Term Loan Facility will accrue interest at an annual rate equal to the greater of (a) Term SOFR (as defined in the Credit Agreement) and (b) 4.75% per annum, plus an applicable margin of 7% (the Applicable Margin). Accrued interest on the Term Loans is payable monthly in arrears. Upon the occurrence, and during the continuance, of an Event of Default (as defined in the Credit Agreement), Perceptive may make a written election for the Applicable Margin to automatically increase by an additional 4% per annum.

Amortization and Prepayment

Prior to the Maturity Date, there will be no scheduled p

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XGN_OUT_35 [2025-04-29 09:11:24 -0400] 1181 Bytes | 256 tokens | Cum: 5961 tkns (74.51% of 8k)
==========================================================================

Showing S1 (chunk 4 of 6): rincipal payments under the Perceptive Term Loan Facility. On the Maturity Date, the Company is required to pay Perceptive the aggregate outstanding principal amount of the Term Loans and all accrued and unpaid interest thereon. The Term Loans may be prepaid at any time, subject to a prepayment premium equal to 2% to 10% of the aggregate outstanding principal amount being prepaid, depending on the date of prepayment.

Security Instruments and Warrant

In connection with the Credit Agreement, the Company also entered into a Security Agreement (the Security Agreement), dated as of the Closing Date, with Perceptive, pursuant to which all of its obligations under the Credit Agreement are secured by a first lien perfected security interest on substantially all of its existing and after-acquired assets, subject to customary exceptions.

In addition, on the Closing Date, as consideration for

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XGN_OUT_37 [2025-04-29 09:11:25 -0400] 1181 Bytes | 310 tokens | Cum: 6273 tkns (78.41% of 8k)
==========================================================================

Showing S1 (chunk 5 of 6): the Credit Agreement, the Company issued to Perceptive a warrant certificate (the Warrant Certificate) to purchase up to 1,150,000 shares (the Warrant Shares) of the Companys common stock, par value $0.001 per share (the Common Stock). 400,000 Warrant Shares (the Tranche A Warrant Shares) vested and became exercisable on the Closing Date, 150,000 Warrant Shares (the Tranche B Warrant Shares) will vest and become exercisable on the Tranche B Borrowing Date, 150,000 Warrant Shares (the Tranche C Warrant Shares) will vest and become exercisable on the Tranche C Borrowing Date and 450,000 Warrant Shares (the Tranche D Warrant Shares and together with the Tranche A Warrant Shares, Tranche B Warrant Shares and Tranche C Warrant Shares, the Warrant Shares) will vest and become exercisable on the Tranche D Borrowing Date, if such borrowing is made. The per share exercise price for (i) 50% of th

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XGN_OUT_39 [2025-04-29 09:11:26 -0400] 790 Bytes | 214 tokens | Cum: 6489 tkns (81.11% of 8k)
==========================================================================

Showing S1 (chunk 6 of 6): e Tranche A Warrant Shares is $4.96 and (ii) the remaining balance of the Tranche A Warrant Shares is $5.58. Additionally, the per share exercise price for (i) 50% of each of the Tranche B Warrant Shares, the Tranche C Warrant Shares and the Tranche D Warrant Shares will be equal to the 10-day VWAP of the Common Stock on the business day immediately

preceding the Tranche B Borrowing Date, Tranche C Borrowing Date and Tranche D Borrowing Date, as applicable, and (ii) the remaining balance of each o...

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

XGN_OUT_41 [2025-04-29 09:11:35 -0400] 6540 Bytes | 1823 tokens | Cum: 8314 tkns (103.92% of 8k)
==========================================================================

This is our set of metrics for Exagen.
Please analyze the numbers.

+---------------------+-----------------------+-------------------------+-----------------------+
| Volume: 228,938 | Perf Month: 56.84% | Option/Short: Yes / Yes | Sales Y/Y TTM: 5.89% |
+---------------------+-----------------------+-------------------------+-----------------------+
| Avg Volume: 121.33K | Perf Quarter: 64.60% | Short Float: 0.66% | ROE: -93.78% |
+---------------------+-----------------------+-------------------------+-----------------------+
| Rel Volume: 1.94 | Index: - | Short Ratio: 0.50 | ROI: -48.47% |
+---------------------+-----------------------+-------------------------+-----------------------+
| RSI (14): 79.92 | Market Cap: 119.02M | Short Interest: 0.06M | Sales Surprise: 0.45% |
+---------------------+-----------------------+-------------------------+-----------------------+
| ATR (14): 0.54 | Shs Outstand: 17.64M | Beta: 1.44 | EPS Surprise: 21.87% |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA20: 43.18% | Shs Float: 9.17M | Sales Q/Q: -0.80% | P/E: - |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA50: 65.80% | Inst Own: 33.80% | Sales past 5Y: 6.91% | Earnings: May 05 BMO |
+---------------------+-----------------------+-------------------------+-----------------------+
| SMA200: 90.13% | Insider Own: 48.77% | Employees: 209 | |
+---------------------+-----------------------+-------------------------+-----------------------+
| Perf Week: 50.11% | Insider Trans: -5.45% | Debt/Eq: 2.45 | |
+---------------------+-----------------------+-------------------------+-----------------------+

The next section covers any insider trading by Exagen officers or majority shareholders (if available).

Inside Trans: EXAGEN INC. (XGN) by NMSIC Co-Investment Fund, L.P. (Unknown Title) on 2025-03-25
- Common Stock: 350000 shares at $3.3 (I)

Inside Trans: EXAGEN INC. (XGN) by ABALLI JOHN (President and CEO) on 2025-02-28
- Common Stock: 8621 shares at $2.465 (D)

Inside Trans: EXAGEN INC. (XGN) by ABALLI JOHN (President and CEO) on 2025-02-21
- Common Stock: 112500 shares at $0 (D)
- Stock Option(right to buy): 75000 shares at $3.58 (D)

Inside Trans: EXAGEN INC. (XGN) by Black Jeffrey G. (Chief Financial Officer) on 2025-02-21
- Common Stock: 15000 shares at $0 (D)
- Stock Option(right to buy): 10000 shares at $3.58 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 55641000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -15115000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 6.65
Average Volume: 120333.8
30-Day High: 6.65
30-Day Low: 3.59

[Detailed Financials: TTM 2024]
- Total Assets: $44,689,000.00
- Total Liabilities: $35,149,000.00
- Total Equity: $9,540,000.00
- Current Assets: $36,455,000.00
- Current Liabilities: $13,506,000.00

[Income Statement: TTM 2024]
- Revenue: $55,641,000.00
- Net Income: $-15,115,000.00
- Gross Profit: $33,112,000.00
- Operating Income: $-13,636,000.00
- Earnings Per Share (EPS): -0.83

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-14,457,000.00

[Detailed Financials: FY 2024]
- Total Assets: $44,689,000.00
- Total Liabilities: $35,149,000.00
- Total Equity: $9,540,000.00
- Current Assets: $36,455,000.00
- Current Liabilities: $13,506,000.00

[Income Statement: FY 2024]
- Revenue: $55,641,000.00
- Net Income: $-15,115,000.00
- Gross Profit: $33,112,000.00
- Operating Income: $-13,636,000.00
- Earnings Per Share (EPS): -0.83

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-14,457,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Exagen (XGN).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Exagen.

2) MARKET_SCORE[]
This conversation was initiated because XGN is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for XGN.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, XGN could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect XGN to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Exagen.

11) ETHICAL_RATING[]
Rate Exagen’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Exagen.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

XGN_IN_43 [2025-04-29 09:11:35 -0400] 126 Bytes | 29 tokens | Cum: 8571 tkns (107.14% of 8k)
==========================================================================

====================================
[2025-04-29 09:11:35] # Analysis Completed
Elapsed Time: 28.50 seconds